Moderna raises vaccine supply estimate
Says it will make at least 600 million doses this year
Moderna said it will increase supply of its Covid-19 vaccine, from its original base-case global production estimate of 500 million to at least 600 million doses for 2021. The company stated that it is continuing to invest and hire staff to build up to potentially 1 billion doses for the year.
Domestically, Moderna said it expects about 100 million doses to be available in the US by the end of Q1, with 200 million available by the end of Q2. The biotech reported that approximately 18 million doses have been supplied to the US government to date. Its vaccine received emergency use authorization from the FDA on Dec. 18 for individuals 18 years or age and older.
The news comes after Pfizer and BioNTech SE announced a second agreement before the holidays with the US government to supply an additional 100 million doses of their vaccine from production facilities in North America, bringing the total number of expected delivered doses to 200 million.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
